JP2019529581A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529581A5 JP2019529581A5 JP2019540308A JP2019540308A JP2019529581A5 JP 2019529581 A5 JP2019529581 A5 JP 2019529581A5 JP 2019540308 A JP2019540308 A JP 2019540308A JP 2019540308 A JP2019540308 A JP 2019540308A JP 2019529581 A5 JP2019529581 A5 JP 2019529581A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- gain
- patient
- missense mutation
- function missense
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662406859P | 2016-10-11 | 2016-10-11 | |
| US62/406,859 | 2016-10-11 | ||
| US201762457759P | 2017-02-10 | 2017-02-10 | |
| US62/457,759 | 2017-02-10 | ||
| US201762502299P | 2017-05-05 | 2017-05-05 | |
| US62/502,299 | 2017-05-05 | ||
| PCT/US2017/055970 WO2018093484A1 (en) | 2016-10-11 | 2017-10-10 | Lasofoxifene treatment of er+ breast cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021022514A Division JP7247241B2 (ja) | 2016-10-11 | 2021-02-16 | Ｅｒ＋乳がんのラソフォキシフェン処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019529581A JP2019529581A (ja) | 2019-10-17 |
| JP2019529581A5 true JP2019529581A5 (enExample) | 2020-11-19 |
| JP6892151B2 JP6892151B2 (ja) | 2021-06-23 |
Family
ID=60186386
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019540308A Active JP6892151B2 (ja) | 2016-10-11 | 2017-10-10 | Ｅｒ＋乳がんのラソフォキシフェン処置 |
| JP2021022514A Active JP7247241B2 (ja) | 2016-10-11 | 2021-02-16 | Ｅｒ＋乳がんのラソフォキシフェン処置 |
| JP2023003699A Active JP7418052B2 (ja) | 2016-10-11 | 2023-01-13 | Ｅｒ＋乳がんのラソフォキシフェン処置 |
| JP2023219161A Active JP7774896B2 (ja) | 2016-10-11 | 2023-12-26 | Ｅｒ＋乳がんのラソフォキシフェン処置 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021022514A Active JP7247241B2 (ja) | 2016-10-11 | 2021-02-16 | Ｅｒ＋乳がんのラソフォキシフェン処置 |
| JP2023003699A Active JP7418052B2 (ja) | 2016-10-11 | 2023-01-13 | Ｅｒ＋乳がんのラソフォキシフェン処置 |
| JP2023219161A Active JP7774896B2 (ja) | 2016-10-11 | 2023-12-26 | Ｅｒ＋乳がんのラソフォキシフェン処置 |
Country Status (20)
| Country | Link |
|---|---|
| US (8) | US20180098963A1 (enExample) |
| EP (2) | EP4035662A1 (enExample) |
| JP (4) | JP6892151B2 (enExample) |
| KR (5) | KR20240007720A (enExample) |
| CN (3) | CN110099680B (enExample) |
| AU (3) | AU2017360365B2 (enExample) |
| BR (1) | BR112019007254A2 (enExample) |
| CA (1) | CA3040266A1 (enExample) |
| DK (1) | DK3525774T3 (enExample) |
| ES (1) | ES2909576T3 (enExample) |
| IL (2) | IL284875B (enExample) |
| MX (2) | MX387856B (enExample) |
| NZ (1) | NZ752443A (enExample) |
| PL (1) | PL3525774T3 (enExample) |
| PT (1) | PT3525774T (enExample) |
| RU (1) | RU2019114079A (enExample) |
| SG (2) | SG11201903236SA (enExample) |
| TW (4) | TWI729227B (enExample) |
| WO (2) | WO2018093484A1 (enExample) |
| ZA (1) | ZA201902454B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109078006B (zh) | 2016-03-29 | 2021-04-20 | 深圳市药欣生物科技有限公司 | 一种帕布昔利布的药物制剂及其制备方法 |
| NZ752443A (en) | 2016-10-11 | 2022-11-25 | Univ Duke | Lasofoxifene treatment of er+ breast cancer |
| CN117771239A (zh) | 2018-04-10 | 2024-03-29 | 杜克大学 | 乳腺癌的拉索昔芬治疗 |
| CN114306245A (zh) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | 无定形固体分散体的药物组合物及其制备方法 |
| GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
| WO2023230222A1 (en) * | 2022-05-25 | 2023-11-30 | Sermonix Pharmaceuticals, Inc. | Lasofoxifene combination treatment of er+ breast cancer that has progressed on a cdk4/6 inhibitor |
| WO2025075631A1 (en) | 2023-10-06 | 2025-04-10 | Sermonix Pharmaceuticals, Inc. | Lasofoxifene treatment of endocrine therapy resistant er+ cancer |
| MX2023013107A (es) * | 2023-11-06 | 2025-06-02 | Centro De Investig Y De Estudios Avanzados Del I P N | Composiciones sinergicas de loratadina-raloxifeno-sorafenib para el tratamiento de cancer hepatico. |
| WO2025122504A1 (en) * | 2023-12-04 | 2025-06-12 | Foundation Medicine, Inc. | Esr1 mutations, esr1 co-occurring mutations, and uses thereof |
| WO2025165887A1 (en) * | 2024-01-30 | 2025-08-07 | Sermonix Pharmaceuticals, Inc. | Lasofoxifene treatment of er+ cancers with constitutively active esr1 mutations |
| WO2026096820A1 (en) * | 2024-10-30 | 2026-05-07 | Sermonix Pharmaceuticals, Inc. | Neoadjuvant treatment of er+ breast cancer with lasofoxifene |
| WO2026095931A1 (en) * | 2024-10-30 | 2026-05-07 | Sermonix Pharmaceuticals, Inc. | Neoadjuvant treatment of er+ breast cancer with lasofoxifene |
| CN119842900A (zh) * | 2025-01-17 | 2025-04-18 | 厦门飞朔生物技术有限公司 | 一种可用于乳腺癌内分泌耐药治疗指导的人esr1基因突变检测试剂盒 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
| US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| UA51676C2 (uk) | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
| IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
| HN1996000101A (es) | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
| US20040044080A1 (en) | 1997-10-28 | 2004-03-04 | Place Virgil A. | Treatment of dyspareunia with topically administered nitroglycerin formulations |
| CA2335361A1 (en) | 1998-06-19 | 1999-12-23 | Senju Pharmaceutical Co., Ltd. | Medicament for reducing side effects of adrenocortical hormones |
| YU26700A (sh) | 1999-05-24 | 2002-06-19 | Pfizer Products Inc. | Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin |
| EP1086692A3 (en) | 1999-07-28 | 2003-07-09 | Pfizer Products Inc. | Estrogen agonists and antagonists for multiple indications |
| US6436977B1 (en) | 1999-09-29 | 2002-08-20 | Pfizer Inc. | Dosing regimens for lasofoxifene |
| CO5271697A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona |
| RU2342145C2 (ru) | 2000-01-28 | 2008-12-27 | Андорешерш, Инк. | Селективные модуляторы рецептора эстрогена в комбинации с эстрогенами |
| DE10039199A1 (de) | 2000-08-10 | 2002-02-21 | Schering Ag | Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen |
| ES2228932T3 (es) | 2000-08-11 | 2005-04-16 | Wyeth | Procedimiento de tratamiento del carcinoma positivo de estrogenos. |
| AU2002235348A1 (en) | 2001-01-17 | 2002-07-30 | Praecis Pharmaceuticals Inc. | Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators |
| AU781168B2 (en) | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
| DK1487790T3 (da) | 2002-03-28 | 2010-05-10 | Pfizer Prod Inc | Renset lasofoxifen og fremgangsmåde til opensning af racemisk lasofoxifen ved omkrystallisering |
| PA8576201A1 (es) | 2002-07-10 | 2004-05-26 | Pfizer Prod Inc | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco |
| CN102357248A (zh) | 2004-10-20 | 2012-02-22 | 恩多研究公司 | 单独的性甾体前体或与选择性雌激素受体调节剂联合用于防治绝经后女性的阴道疾病和病症 |
| US20090012052A1 (en) | 2006-11-09 | 2009-01-08 | Ore Pharmaceuticals Inc. | Method for treating er+ breast cancer |
| US20110015134A1 (en) | 2007-04-16 | 2011-01-20 | Retsky Michael W | Method of treatment for early stage cancer |
| CZ2007373A3 (cs) | 2007-05-29 | 2008-12-10 | Zentiva, A. S | Zpusob prípravy lasofoxifenu |
| US20110182888A1 (en) | 2008-04-08 | 2011-07-28 | Peter Ordentlich | Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator |
| WO2009137543A2 (en) * | 2008-05-06 | 2009-11-12 | Ore Pharmaceuticals Inc. | Methods for breast cancer screening and treatment |
| CA2750565C (en) | 2009-01-30 | 2015-10-20 | Glaxosmithkline Llc | Crystalline n-{(1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
| EP2239570A1 (en) * | 2009-04-10 | 2010-10-13 | PamGene B.V. | Method for determining the estrogen receptor status of breast cancer |
| HUE052510T2 (hu) * | 2009-05-27 | 2021-05-28 | Ptc Therapeutics Inc | Módszerek a rák és a nem daganatos állapotok kezelésére |
| US20130253035A1 (en) | 2010-08-16 | 2013-09-26 | Duke University | Camkk-beta as a target for treating cancer |
| US20120052508A1 (en) * | 2010-08-27 | 2012-03-01 | Rutgers, The State University Of New Jersey | Genetic markers and diagnostic methods for resistance of breast cancer to hormonal therapies |
| BR112013022882A2 (pt) | 2011-03-11 | 2016-12-20 | Merrimack Pharmaceuticals Inc | uso de inibidores de receptores da família egfr no tratamento de cânceres de mama hormônio-refratários |
| JP2014516964A (ja) | 2011-05-18 | 2014-07-17 | メルク・シャープ・アンド・ドーム・コーポレーション | 治療用抗ｉｇｆ１ｒ合剤 |
| WO2013056178A2 (en) * | 2011-10-14 | 2013-04-18 | Foundation Medicine, Inc. | Novel estrogen receptor mutations and uses thereof |
| EP2791128A4 (en) | 2011-12-16 | 2015-04-22 | Olema Pharmaceuticals Inc | NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF |
| US20160038506A1 (en) | 2012-02-14 | 2016-02-11 | Repros Therapeutics Inc. | Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof |
| US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
| US9204286B1 (en) | 2013-03-15 | 2015-12-01 | Sprint Communications Company L.P. | System and method of branding and labeling a mobile device |
| US9855270B2 (en) * | 2014-03-13 | 2018-01-02 | Genentech, Inc. | Methods and compositions for modulating estrogen receptor mutants |
| AU2015228859A1 (en) | 2014-03-13 | 2016-07-07 | F. Hoffmann-La Roche Ag | Therapeutic combinations with estrogen receptor modulators |
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| RS67458B1 (sr) | 2014-03-28 | 2025-12-31 | Univ Duke | Lečenje kancera dojke pozitivnog na receptor estrogena upotrebom selektivnih modulatora receptora estrogena |
| CN111956653B (zh) | 2014-05-08 | 2023-06-30 | 上海市生物医药技术研究院 | 双炔失碳酯组合物和疾病治疗方法 |
| AU2015341700A1 (en) | 2014-11-07 | 2017-06-08 | Lipoxen Technologies Limited | Method for treatment of primary hormone resistant endometrial and breast cancers |
| JP2018514511A (ja) | 2015-04-14 | 2018-06-07 | アトッサ ジェネティックス インク． | 乳房障害とエストロゲン関連障害の処置のための組成物と方法 |
| KR102676629B1 (ko) * | 2015-04-29 | 2024-06-18 | 래디어스 파마슈티컬스, 인코포레이티드 | 암을 치료하는 방법 |
| NZ752443A (en) | 2016-10-11 | 2022-11-25 | Univ Duke | Lasofoxifene treatment of er+ breast cancer |
| WO2018071437A1 (en) | 2016-10-11 | 2018-04-19 | Sermonix Pharmaceuticals, Llc | Lasofoxifene treatment of vva and osteoporosis in survivors of breast cancer and other malignancies |
| US10624874B2 (en) | 2017-01-10 | 2020-04-21 | Zhejiang Jiachi Development Pharmaceuticals Ltd | Lasofoxifene modulation of membrane-initiated estrogen signals and methods for tumor treatment |
| CN117771239A (zh) * | 2018-04-10 | 2024-03-29 | 杜克大学 | 乳腺癌的拉索昔芬治疗 |
| MX2021001857A (es) * | 2018-08-17 | 2021-10-13 | Genentech Inc Star | Metodos de diagnostico y terapeuticos para el tratamiento del cancer de mama. |
| US20240398831A1 (en) | 2021-10-05 | 2024-12-05 | Duke University | Compositions comprising small molecule regulators of tumor immunity and methods of using same |
| GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
| WO2023230222A1 (en) | 2022-05-25 | 2023-11-30 | Sermonix Pharmaceuticals, Inc. | Lasofoxifene combination treatment of er+ breast cancer that has progressed on a cdk4/6 inhibitor |
-
2017
- 2017-10-10 NZ NZ752443A patent/NZ752443A/en unknown
- 2017-10-10 SG SG11201903236SA patent/SG11201903236SA/en unknown
- 2017-10-10 BR BR112019007254-3A patent/BR112019007254A2/pt not_active Application Discontinuation
- 2017-10-10 SG SG10201913951YA patent/SG10201913951YA/en unknown
- 2017-10-10 PL PL17791239T patent/PL3525774T3/pl unknown
- 2017-10-10 KR KR1020247000452A patent/KR20240007720A/ko active Pending
- 2017-10-10 AU AU2017360365A patent/AU2017360365B2/en active Active
- 2017-10-10 CN CN201780073528.3A patent/CN110099680B/zh active Active
- 2017-10-10 KR KR1020217023829A patent/KR102462433B1/ko active Active
- 2017-10-10 DK DK17791239.1T patent/DK3525774T3/da active
- 2017-10-10 CA CA3040266A patent/CA3040266A1/en active Pending
- 2017-10-10 RU RU2019114079A patent/RU2019114079A/ru unknown
- 2017-10-10 ES ES17791239T patent/ES2909576T3/es active Active
- 2017-10-10 KR KR1020197013405A patent/KR102285453B1/ko active Active
- 2017-10-10 IL IL284875A patent/IL284875B/en unknown
- 2017-10-10 CN CN202110143863.4A patent/CN112933082A/zh active Pending
- 2017-10-10 PT PT177912391T patent/PT3525774T/pt unknown
- 2017-10-10 KR KR1020237008605A patent/KR102531354B1/ko active Active
- 2017-10-10 JP JP2019540308A patent/JP6892151B2/ja active Active
- 2017-10-10 WO PCT/US2017/055970 patent/WO2018093484A1/en not_active Ceased
- 2017-10-10 KR KR1020227037620A patent/KR102623130B1/ko active Active
- 2017-10-10 US US15/729,320 patent/US20180098963A1/en not_active Abandoned
- 2017-10-10 CN CN202011320148.5A patent/CN112353796A/zh active Pending
- 2017-10-10 EP EP21215433.0A patent/EP4035662A1/en active Pending
- 2017-10-10 WO PCT/US2017/055974 patent/WO2018071440A1/en not_active Ceased
- 2017-10-10 MX MX2019004184A patent/MX387856B/es unknown
- 2017-10-10 US US16/341,033 patent/US20190231718A1/en not_active Abandoned
- 2017-10-10 EP EP17791239.1A patent/EP3525774B1/en active Active
- 2017-10-11 TW TW106134805A patent/TWI729227B/zh active
- 2017-10-11 TW TW111149243A patent/TWI836808B/zh active
- 2017-10-11 TW TW110124571A patent/TWI790672B/zh active
- 2017-10-11 TW TW113106582A patent/TWI896001B/zh active
-
2018
- 2018-03-28 US US15/939,218 patent/US10258604B2/en active Active
-
2019
- 2019-02-01 US US16/265,109 patent/US10905659B2/en active Active
- 2019-04-10 MX MX2021013911A patent/MX2021013911A/es unknown
- 2019-04-10 IL IL265938A patent/IL265938B/en unknown
- 2019-04-17 ZA ZA2019/02454A patent/ZA201902454B/en unknown
-
2020
- 2020-10-16 US US17/073,253 patent/US20210361596A1/en not_active Abandoned
-
2021
- 2021-02-16 JP JP2021022514A patent/JP7247241B2/ja active Active
-
2022
- 2022-10-09 AU AU2022246480A patent/AU2022246480B2/en active Active
-
2023
- 2023-01-13 JP JP2023003699A patent/JP7418052B2/ja active Active
- 2023-03-30 US US18/193,207 patent/US11980597B2/en active Active
- 2023-12-26 JP JP2023219161A patent/JP7774896B2/ja active Active
-
2024
- 2024-04-08 US US18/629,894 patent/US20250064757A1/en active Pending
- 2024-07-04 US US18/764,274 patent/US12414924B2/en active Active
-
2025
- 2025-01-16 AU AU2025200327A patent/AU2025200327B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108024541B (zh) | 用于治疗癌症的方法 | |
| RU2019114079A (ru) | Лечение er+ рака молочной железы лазофоксифеном | |
| JP2019518765A5 (enExample) | ||
| IL292659A (en) | Methods for treating breast cancer ar plus | |
| WO2015082990A1 (en) | Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer | |
| JP2022510410A5 (enExample) | ||
| JP7667132B2 (ja) | Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置 | |
| JP2024538402A5 (enExample) | ||
| RU2016148441A (ru) | Способ лечения pr-положительного люминального а-типа рака молочной железы ингибитором pi3k пиктилисибом | |
| JP2019508476A5 (enExample) | ||
| US20240173306A1 (en) | Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor | |
| JP7376540B2 (ja) | リンパ節陽性の初期ホルモン受容体陽性かつヒト上皮成長因子受容体２陰性乳癌の補助治療のための内分泌療法とアベマシクリブとの組み合わせ | |
| JP2026016396A (ja) | 乳がんの治療のための併用療法 | |
| CN107249587B (zh) | 用于治疗乳腺癌的抗组胺药 | |
| EP3654967A1 (en) | Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer | |
| EP3919058A1 (en) | Use of composition containing cdk4/6 inhibitor in combination with anastrozole in preparation of medicament for treating tumor diseases | |
| US20230381156A1 (en) | Treatment of breast cancer using combination therapies comprising gdc-9545 and ipatasertib | |
| JP7846700B2 (ja) | Ｇｄｃ－９５４５とアベマシクリブ又はリボシクリブとを含む併用療法を使用する乳がんの治療 | |
| WO2024246824A1 (en) | Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer | |
| HK40066922A (zh) | 使用包含atp竞争性akt抑制剂、cdk4/6抑制剂和氟维司群的组合疗法来治疗乳腺癌 | |
| HK40101825A (zh) | 使用包括gdc-9545和依帕他赛的组合疗法治疗乳腺癌 | |
| JP2023086719A (ja) | Ｃｄｋ４及び６阻害剤で以前に治療された患者におけるホルモン受容体陽性でヒト上皮成長因子受容体２陰性の進行性又は転移性乳がんの治療のためのフルベストラントとのｃｄｋ４及び６阻害剤の併用 | |
| HK40110657A (zh) | 用於治疗癌症的cdk4抑制剂 | |
| HK40062029A (en) | Use of composition containing cdk4/6 inhibitor in combination with anastrozole in preparation of medicament for treating tumor diseases |